A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee

June 20, 2019 updated by: Afferent Pharmaceuticals, Inc.

The purpose of this study is to assess the efficacy of a single dose level of gefapixant (AF-219/MK-7264) in subjects with moderate to severe pain associated with osteoarthritis (OA) of the knee compared with placebo after 4 weeks of treatment.

The study will also assess the safety and tolerability, changes in physical function, stiffness, treatment response and health outcomes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Subjects who satisfy entry criteria at Screening will enter the Washout Phase, discontinuing their current nonsteroidal anti-inflammatory drug (NSAID) therapy.

Up to 220 subjects who fulfill flare (and other entry) criteria will be randomized to gefapixant or placebo.

Subjects will complete Treatment Visits 1, 2, 3, and 4 weeks after starting study drug. At each Treatment Visit, subjects will undergo efficacy assessments and safety procedures. During the Washout and Treatment Phases subjects will complete the 'average pain' Numeric Pain Rating Scale (NPRS) and count of rescue medication used for the preceding 24 hours.

Subjects will return 2 weeks after their last Treatment Visit (for a Follow-Up Visit).

Study Type

Interventional

Enrollment (Actual)

171

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Phoenix, Arizona, United States, 85018
        • Afferent Investigative Site
      • Phoenix, Arizona, United States, 85027
        • Afferent Investigative Site
    • California
      • San Diego, California, United States, 92108
        • Afferent Investigative Site
    • Florida
      • Clearwater, Florida, United States, 33756
        • Afferent Investigative Site
      • Orlando, Florida, United States, 32806
        • Afferent Investigative Site
      • Pinellas Park, Florida, United States, 33781
        • Afferent Investigative Site
    • Georgia
      • Atlanta, Georgia, United States, 30329
        • Afferent Investigative Site
    • Kansas
      • Wichita, Kansas, United States, 67203
        • Afferent Investigative Site
    • Massachusetts
      • New Bedford, Massachusetts, United States, 02740
        • Afferent Investigative Site
      • Watertown, Massachusetts, United States, 02472
        • Afferent Investigative Site
    • Michigan
      • Troy, Michigan, United States, 48098
        • Afferent Investigative Site
    • Mississippi
      • Olive Branch, Mississippi, United States, 38654
        • Afferent Investigative Site
    • Missouri
      • Hazelwood, Missouri, United States, 63042
        • Afferent Investigative Site
      • Saint Louis, Missouri, United States, 63141
        • Afferent Investigative Site
    • New Mexico
      • Albuquerque, New Mexico, United States, 87102
        • Afferent Investigative Site
    • North Carolina
      • Asheville, North Carolina, United States, 28803
        • Afferent Investigative Site
      • Greensboro, North Carolina, United States, 27408
        • Afferent Investigative Site
      • Winston-Salem, North Carolina, United States, 27103
        • Afferent Investigative Site
    • Ohio
      • Cincinnati, Ohio, United States, 45219
        • Afferent Investigative Site
      • Toledo, Ohio, United States, 43623
        • Afferent Investigative Site
    • Oregon
      • Medford, Oregon, United States, 97504
        • Afferent Investigative Site
    • Pennsylvania
      • Duncansville, Pennsylvania, United States, 16635
        • Afferent Investigative Site
    • Rhode Island
      • Warwick, Rhode Island, United States, 02886
        • Afferent Investigative Site
    • South Carolina
      • Greer, South Carolina, United States, 29650
        • Afferent Investigative Site
      • Mount Pleasant, South Carolina, United States, 29464
        • Afferent Investigative Site
    • Texas
      • Austin, Texas, United States, 78705
        • Afferent Investigative Site
      • Dallas, Texas, United States, 75231
        • Afferent Investigative Site
      • Houston, Texas, United States, 77062
        • Afferent Investigative Site
      • San Antonio, Texas, United States, 78209
        • Afferent Investigative Site
      • San Antonio, Texas, United States, 78229
        • Afferent Investigative Site
    • Utah
      • Clinton, Utah, United States, 84015
        • Afferent Investigative Site
    • Virginia
      • Roanoke, Virginia, United States, 24018
        • Afferent Investigative Site
    • Washington
      • Renton, Washington, United States, 98057
        • Afferent Investigative Site
    • Wisconsin
      • Kenosha, Wisconsin, United States, 53142
        • Afferent Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men or women
  • Women of child bearing potential must not be pregnant during the study and must use two forms of birth control
  • Men and their female partners must use two forms of birth control
  • Clinical and radiographic evidence of chronic knee osteoarthritis
  • An average NPRS score of >=5 and <=9 over a 4-7 day washout period of their previous osteoarthritis medications
  • Ambulatory
  • Have provided written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Sugar pill
Drug: Sugar Pill
Placebo
Experimental: Gefapixant
Drug: Gefapixant
BID
Other Names:
  • AF-219
  • MK-7264

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Primary Efficacy Endpoint of This Study is the Weekly Average Daily NPRS (Average Pain)
Time Frame: 2 Weeks
Subjects were instructed to select a number on a scale that best described their knee arthritis pain during the past 24 hours. The scale was between 0 and 10 where 0 was no pain and 10 was the worst possible pain. The scale was completed by telephone (an interactive voice response system [IVRS]) every evening before bedtime.
2 Weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
WOMAC Scores
Time Frame: 4 Weeks
This is the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). This is a questionnaire that asks subjects to evaluate their pain, stiffness, and physical activities affecting their knee over the past 48 hours. Subjects evaluate their pain, stiffness and physical activities by selecting a number between 0 and 10 where 0 is no pain/no stiffness/no difficulty doing physical activities and 10 is extreme pain/extreme stiffness/extreme difficulty doing physical activities. The questionnaire was administered at Screening, Baseline and at the end of Week 4 by telephone (an interactive voice response system [IVRS]) before bedtime. The scores for each category are totaled (range is 0-100). A lower total score means less pain and a higher total score means greater pain.
4 Weeks
SF-36
Time Frame: 4 Weeks
The SF-36 (acute version 2) was a 36 question survey administered at Baseline and at the end of study or early termination (Week 4). The questionnaire contained numerous domain scores to evaluate physical function, mental function, general health, bodily pain, social functioning and vitality. The question of interest for the analysis was question #1 regarding walking pain. Scores range from 0 - 100. A lower score means decreased pain while walking and a higher score means increased pain while walking.
4 Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Afferent Pharmaceuticals, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 29, 2012

Primary Completion (Actual)

November 11, 2013

Study Completion (Actual)

November 21, 2013

Study Registration Dates

First Submitted

March 12, 2012

First Submitted That Met QC Criteria

March 13, 2012

First Posted (Estimate)

March 15, 2012

Study Record Updates

Last Update Posted (Actual)

June 27, 2019

Last Update Submitted That Met QC Criteria

June 20, 2019

Last Verified

June 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 7264-004
  • AF219004 (Other Identifier: Afferent Pharmaceuticals)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis of the Knee

Clinical Trials on Sugar Pill

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe